Ocular Therapeutix, Inc.OCULNASDAQ
Loading
R&D Expenses Over TimeExpanding
Percentile Rank100
3Y CAGR+54.5%
5Y CAGR+47.0%
Year-over-Year Change
Research and development spending
3Y CAGR
+54.5%/yr
vs +9.7%/yr prior
5Y CAGR
+47.0%/yr
Recent acceleration
Acceleration
+44.8pp
Accelerating
Percentile
P100
Near historical high
vs 5Y Ago
6.9x
Strong expansion
Streak
5 yr
Consecutive growthExpanding
| Period | Value | YoY Change |
|---|---|---|
| TTM | $197.10M | +54.4% |
| 2024 | $127.64M | +109.0% |
| 2023 | $61.05M | +14.2% |
| 2022 | $53.46M | +6.7% |
| 2021 | $50.08M | +74.5% |
| 2020 | $28.69M | -30.2% |
| 2019 | $41.09M | +11.3% |
| 2018 | $36.91M | +19.5% |
| 2017 | $30.88M | +14.1% |
| 2016 | $27.07M | - |